Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor
Top Cited Papers
- 1 November 2006
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 2 (11) , 602-610
- https://doi.org/10.1038/ncprheum0336
Abstract
Ature Clinical Practice Oncology will deliver timely interpretations of key research developments, translating the latest findings into clinical practice. Our Editor-in-Chief and international Advisory Board will ensure comprehensive coverage of topical issues throughout the year, with the highest standards of editorial quality and integrity that are hallmarks of Nature Publishing Group.Keywords
This publication has 49 references indexed in Scilit:
- Advances in the therapy of Wegener's granulomatosisCurrent Opinion in Rheumatology, 2006
- British Thoracic Society (BTS) recommendations for assessing risk and managing tuberculosis in patients due to start anti-TNF-α treatmentsRheumatology, 2005
- Defective Innate Antibacterial Host Responses during Murine Klebsiella pneumoniae Bacteremia: Tumor Necrosis Factor (TNF) Receptor 1 Deficiency versus Therapy with Anti–TNF-αClinical Infectious Diseases, 2005
- Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanerceptAlimentary Pharmacology & Therapeutics, 2005
- Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic reviewThe Lancet Infectious Diseases, 2004
- The effect of etanercept and infliximab on the production of tumour necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte culturesCytokine, 2003
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- Tumor necrosis factor-α is required in the protective immune response against mycobacterium tuberculosis in miceImmunity, 1995